Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

217 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated Genes.
Kratochwil C, Giesel FL, Heussel CP, Kazdal D, Endris V, Nientiedt C, Bruchertseifer F, Kippenberger M, Rathke H, Leichsenring J, Hohenfellner M, Morgenstern A, Haberkorn U, Duensing S, Stenzinger A. Kratochwil C, et al. Among authors: duensing s. J Nucl Med. 2020 May;61(5):683-688. doi: 10.2967/jnumed.119.234559. Epub 2019 Oct 10. J Nucl Med. 2020. PMID: 31601699 Free article.
Intraindividual Comparison of 18F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study.
Kesch C, Vinsensia M, Radtke JP, Schlemmer HP, Heller M, Ellert E, Holland-Letz T, Duensing S, Grabe N, Afshar-Oromieh A, Wieczorek K, Schäfer M, Neels OC, Cardinale J, Kratochwil C, Hohenfellner M, Kopka K, Haberkorn U, Hadaschik BA, Giesel FL. Kesch C, et al. Among authors: duensing s. J Nucl Med. 2017 Nov;58(11):1805-1810. doi: 10.2967/jnumed.116.189233. Epub 2017 May 4. J Nucl Med. 2017. PMID: 28473595 Free article.
High-risk prostate cancer: a disease of genomic instability.
Tapia-Laliena MA, Korzeniewski N, Hohenfellner M, Duensing S. Tapia-Laliena MA, et al. Among authors: duensing s. Urol Oncol. 2014 Nov;32(8):1101-7. doi: 10.1016/j.urolonc.2014.02.005. Epub 2014 Jun 13. Urol Oncol. 2014. PMID: 24931269 Review.
Mutations in BRCA2 and taxane resistance in prostate cancer.
Nientiedt C, Heller M, Endris V, Volckmar AL, Zschäbitz S, Tapia-Laliena MA, Duensing A, Jäger D, Schirmacher P, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S. Nientiedt C, et al. Among authors: duensing a, duensing s. Sci Rep. 2017 Jul 4;7(1):4574. doi: 10.1038/s41598-017-04897-x. Sci Rep. 2017. PMID: 28676659 Free PMC article.
Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer.
Kesch C, Radtke JP, Wintsche A, Wiesenfarth M, Luttje M, Gasch C, Dieffenbacher S, Pecqueux C, Teber D, Hatiboglu G, Nyarangi-Dix J, Simpfendörfer T, Schönberg G, Dimitrakopoulou-Strauss A, Freitag M, Duensing A, Grüllich C, Jäger D, Götz M, Grabe N, Schweiger MR, Pahernik S, Perner S, Herpel E, Roth W, Wieczorek K, Maier-Hein K, Debus J, Haberkorn U, Giesel F, Galle J, Hadaschik B, Schlemmer HP, Hohenfellner M, Bonekamp D, Sültmann H, Duensing S. Kesch C, et al. Among authors: duensing a, duensing s. Sci Rep. 2018 Nov 12;8(1):16708. doi: 10.1038/s41598-018-35058-3. Sci Rep. 2018. PMID: 30420756 Free PMC article.
The BRCA2 mutation status shapes the immune phenotype of prostate cancer.
Jenzer M, Keß P, Nientiedt C, Endris V, Kippenberger M, Leichsenring J, Stögbauer F, Haimes J, Mishkin S, Kudlow B, Kaczorowski A, Zschäbitz S, Volckmar AL, Sültmann H, Jäger D, Duensing A, Schirmacher P, Hohenfellner M, Grüllich C, Stenzinger A, Duensing S. Jenzer M, et al. Among authors: duensing a, duensing s. Cancer Immunol Immunother. 2019 Oct;68(10):1621-1633. doi: 10.1007/s00262-019-02393-x. Epub 2019 Sep 23. Cancer Immunol Immunother. 2019. PMID: 31549213 Free PMC article.
PARP inhibition in prostate cancer.
Nientiedt C, Duensing A, Zschäbitz S, Jäger D, Hohenfellner M, Stenzinger A, Duensing S. Nientiedt C, et al. Among authors: duensing a, duensing s. Genes Chromosomes Cancer. 2021 May;60(5):344-351. doi: 10.1002/gcc.22903. Epub 2020 Oct 28. Genes Chromosomes Cancer. 2021. PMID: 33084183 Review.
High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel.
Nientiedt C, Endris V, Jenzer M, Mansour J, Sedehi NTP, Pecqueux C, Volckmar AL, Leichsenring J, Neumann O, Kirchner M, Hoveida S, Lantwin P, Kaltenecker K, Dieffenbacher S, Gasch C, Hofer L, Franke D, Tosev G, Görtz M, Schütz V, Radtke JP, Nyarangi-Dix J, Hatiboglu G, Simpfendörfer T, Schönberg G, Isaac S, Teber D, Koerber SA, Christofi G, Czink E, Kreuter R, Apostolidis L, Kratochwil C, Giesel F, Haberkorn U, Debus J, Sültmann H, Zschäbitz S, Jäger D, Duensing A, Schirmacher P, Grüllich C, Hohenfellner M, Stenzinger A, Duensing S. Nientiedt C, et al. Among authors: duensing a, duensing s. Urol Oncol. 2020 Jul;38(7):637.e17-637.e27. doi: 10.1016/j.urolonc.2020.03.001. Epub 2020 Apr 10. Urol Oncol. 2020. PMID: 32280037 Free article.
Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.
Nientiedt C, Budczies J, Endris V, Kirchner M, Schwab C, Jurcic C, Behnisch R, Hoveida S, Lantwin P, Kaczorowski A, Geisler C, Dieffenbacher S, Falkenbach F, Franke D, Görtz M, Heller M, Himmelsbach R, Pecqueux C, Rath M, Reimold P, Schütz V, Simunovic I, Walter E, Hofer L, Gasch C, Schönberg G, Pursche L, Hatiboglu G, Nyarangi-Dix J, Sültmann H, Zschäbitz S, Koerber SA, Jäger D, Debus J, Duensing A, Schirmacher P, Hohenfellner M, Stenzinger A, Duensing S. Nientiedt C, et al. Among authors: duensing a, duensing s. Urol Oncol. 2022 Jan;40(1):8.e11-8.e18. doi: 10.1016/j.urolonc.2021.06.024. Epub 2021 Jul 26. Urol Oncol. 2022. PMID: 34325986 Free article.
217 results